Related Experiment Video
Updated: Jan 14, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Hypercontractility and Oxidative Stress Drive Creatine Kinase Dysfunction in Hypertrophic Cardiomyopathy
Anton Xu1, David Weissman1, Katharina J Ermer1
1Department of Translational Science, University Clinic Würzburg, Würzburg, Germany (A.X., D.W., K.J.E., J.M.F., F.S., E.G., J.D., M.K., A.G.N., C.M., V.S.).
Insights
Hypertrophic cardiomyopathy (HCM) involves impaired creatine kinase (CK) function due to oxidative stress from hypercontractility. Targeting hypercontractility and oxidative stress may restore energy balance and reduce arrhythmia risk in HCM.
Area of Science:
- Cardiology
- Biochemistry
- Molecular Biology
Background:
- Hypertrophic cardiomyopathy (HCM) is a common inherited heart disorder characterized by left ventricular hypertrophy and hypercontractility, leading to an energy deficit.
- Creatine kinase (CK) is crucial for cardiac energy homeostasis, but its role in HCM pathophysiology is not fully understood.
- This study explores how mitochondrial stress and increased hydrogen peroxide (H₂O₂) production in HCM disrupt CK function.
Purpose of the Study:
- To investigate the impact of hypercontractility-driven mitochondrial stress on creatine kinase (CK) function in hypertrophic cardiomyopathy (HCM).
- To elucidate the mechanisms linking mitochondrial reactive oxygen species (ROS) and CK dysfunction in HCM.
- To evaluate potential therapeutic strategies targeting hypercontractility and oxidative stress in HCM.
Main Methods:
- Analyzed myocardial tissue from HCM patients and controls for CK isoforms using various biochemical and proteomic techniques.
- Utilized mouse models, including CK knockout and HCM-associated variants, to study hypercontractility, mitochondrial ROS, and CK function.
- Investigated the effects of pharmacological agents like Ca²⁺ sensitizers, CK inhibitors, and myosin inhibitors on cardiomyocyte function and oxidative stress.
Main Results:
- HCM myocardium showed reduced CK levels and activity, primarily due to oxidative damage.
- In mouse models, hypercontractility induced by EMD-57033 increased mitochondrial H₂O₂, leading to CK inactivation and arrhythmias.
- Mice with enhanced H₂O₂ scavenging and treatment with myosin inhibitor MYK-581 demonstrated protection against oxidative stress, arrhythmias, and preserved CK function.
Conclusions:
- Established a mechanistic link between hypercontractility, mitochondrial ROS, and CK dysfunction in HCM, creating a cycle of energetic impairment.
- Myosin inhibition emerges as a promising therapeutic strategy to address hypercontractility and oxidative stress, thereby restoring cardiac energy balance and reducing arrhythmia risk in HCM.
Background:
Hypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiac disorder marked by left ventricular hypertrophy and hypercontractility. This excessive mechanical workload creates an energetic mismatch in which consumption exceeds production, leading to myocardial energy depletion. Although CK (creatine kinase) plays a key role in cardiac energy homeostasis, its involvement in HCM remains unclear. This study investigates how hypercontractility-driven mitochondrial stress and the resulting increase in mitochondrial H2O2 disrupt CK function in HCM.
Methods:
CK function was analyzed using myocardial left ventricular tissue from 92 patients with HCM (with and without pathogenic sarcomere variants) and 30 non-failing human controls. Myofilament and mitochondrial CK isoforms were measured using mRNA analysis, protein immunoblotting, enzyme activity assays, mass spectrometry, and redox-sensitive proteomics. To explore links between hypercontractility, mitochondrial reactive oxygen species, and CK dysfunction, we used isolated cardiomyocytes from wild-type, mitochondrial-targeted catalase-overexpressing, CK knockout (myofilament and mitochondrial CK deletion), HCM-associated Mybpc3 knock-in, and mito-roGFP2-Orp1 mouse models. We also tested the effects of the Ca2+ sensitizer EMD-57033, the CK inhibitor 1-fluoro-2,4-dinitrobenzene (DNFB), and the myosin inhibitor MYK-581, a mavacamten derivative.
Results:
Our analysis revealed significant reductions in myofilament and mitochondrial CK protein levels, as well as CK activity, in myocardium of patients with HCM, primarily because of oxidative modifications of CK. In isolated mouse cardiomyocytes from wild-type and CK knockouts, hypercontractility induced by EMD-57033 elevated mitochondrial H2O2, causing cellular arrhythmias and CK inactivation. Hypercontractility-induced oxidative stress, arrhythmias, and CK dysfunction were also observed in Mybpc3 knock-in cardiomyocytes. Mitochondrial-targeted catalase-overexpressing mice with enhanced H2O2 scavenging were protected against H2O2-induced (EMD-57033-mediated) arrhythmias and CK dysfunction. MYK-581 treatment in Mybpc3 knock-in cardiomyocytes reduced hypercontractility, lowered H2O2 production and arrhythmias, and preserved CK function. CK inhibition using DNFB in wild-type cardiomyocytes elevated mitochondrial H2O2 levels and triggered cellular arrhythmias. This mitochondrial oxidation was independently confirmed in mito-roGFP2-Orp1 cardiomyocytes exposed to DNFB. Mitochondrial-targeted catalase-overexpressing mice were protected from DNFB-induced oxidative stress and arrhythmogenic events.
Conclusions:
This study reveals a mechanistic link between hypercontractility, mitochondrial reactive oxygen species, and CK dysfunction in HCM, perpetuating a cycle of energetic dysfunction. Targeting hypercontractility and oxidative stress through myosin inhibition offers a strategy to restore energy balance and reduce arrhythmic risk in HCM.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure II: Pathophysiology
Pathophysiology of Cardiac Performance
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Pathophysiology of Heart Failure
Cardiomyopathy IV: Restrictive Cardiomyopathy

